A detailed history of Rhumbline Advisers transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 6,107 shares of AUTL stock, worth $17,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,107
Previous 5,802 5.26%
Holding current value
$17,099
Previous $20,000 10.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.38 - $4.69 $1,030 - $1,430
305 Added 5.26%
6,107 $22,000
Q2 2024

Aug 01, 2024

BUY
$3.33 - $5.68 $11,615 - $19,811
3,488 Added 150.73%
5,802 $20,000
Q1 2024

May 09, 2024

BUY
$5.39 - $7.29 $6,284 - $8,500
1,166 Added 101.57%
2,314 $14,000
Q3 2023

Nov 09, 2023

SELL
$2.32 - $3.36 $185 - $268
-80 Reduced 6.51%
1,148 $2,000
Q2 2023

Aug 08, 2023

BUY
$1.64 - $3.21 $2,013 - $3,941
1,228 New
1,228 $2,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $255M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.